biguanides has been researched along with Injuries in 25 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Injuries: Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aim was to assess the clinical efficacy of a propylbetaine-polihexanide (PP) solution versus normal saline (NS) solution in WBP, assessing inflammatory signs and wound size reduction in patients with pressure ulcers (PUs) or vascular leg ulcers." | 5.22 | Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT. ( Bellingeri, A; Chiari, P; Falciani, F; Moscatelli, A; Peghetti, A; Russo, A; Tino, G; Traspedini, P, 2016) |
| "Prevention of wound infections is a challenge in clinical practice." | 2.87 | Randomized controlled clinical trial on the antiseptic efficacy of polihexanide 0.04% on acute traumatic wounds. ( Brill, FHH; Csuka, E; Hintzpeter, M; Pahl, S; Payne, B; Simmen, HP, 2018) |
| "Wounds were assessed for time of dressing change and overall satisfaction of patients and health care providers." | 2.75 | Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel. ( Abels, C; Daigeler, A; Goertz, O; Hirsch, T; Knie, U; Langer, S; May, T; Steinau, HU, 2010) |
| "Wounds were evenly distributed with respect to etiology and both study groups had a median baseline wound size of 7 cm2." | 2.71 | Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. ( Corbett, LQ; Milne, CT; Motta, GJ, 2004) |
| "The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention." | 2.48 | Extending the TIME concept: what have we learned in the past 10 years?(*). ( Carville, K; Drake, R; Fletcher, J; Leaper, DJ; Schultz, G; Swanson, T, 2012) |
| "Biofilm in chronic wounds impedes the wound healing process." | 1.56 | Synergistic Effect and Antibiofilm Activity of a Skin and Wound Cleanser. ( Bionda, N; D'Arpa, P; McMahon, RE; Poleon, S; Salamone, AB; Salamone, JC, 2020) |
| "Complex stalled wounds feature an alkaline milieu that favors tissue destruction and microbial growth." | 1.46 | Antibacterial activity of polihexanide formulations in a co-culture of HaCaT keratinocytes and Staphylococcus aureus and at different pH levels. ( Andriessen, A; Eberlein, T; Wiegand, C, 2017) |
| "The use of antibiotics to treat wound infections has decreased due to the increased risk of antibiotic resistance ( Swanson et al, 2014 )." | 1.46 | Wound-bed preparation: a vital step in the healing process. ( Barrett, S, 2017) |
| "Thirty-nine deep partial thickness wounds were created with six wounds assigned to one of six treatment groups: (i) PHMB, (ii) Ringer's solution, (iii) hypochlorous acid/sodium hypochlorite, (iv) sterile water, (v) octenidine dihydrochloride, and (vi) octenilin." | 1.46 | Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model. ( Davis, SC; Gil, J; Harding, A; Higa, A; Parajon, F; Solis, M; Valdes, J, 2017) |
| " This study is designed to assess the effect of antimicrobial-impregnated dressing (AMD) combined with negative-pressure wound therapy (NPWT) on skin graft survival." | 1.42 | Antimicrobial-impregnated dressing combined with negative-pressure wound therapy increases split-thickness skin graft engraftment: a simple effective technique. ( Chen, CC; Chew, KY; Kuo, YR; Wu, CC, 2015) |
| "The treatment of chronic skin wounds through the use of a polyhexanide/propyl betaine-based gel, in combination with a secondary dressing, showed significant improvements, such as a 30% reduction of pain at dressing change, the reduction in the size and characteristics of the wounds and a reduction in the levels of exudate." | 1.40 | Evaluation of the effectiveness of a polyhexanide and propyl betaine-based gel in the treatment of chronic wounds. ( Ciprandi, G; Durante, CM; Gallarini, A; Greco, A; Maino, C; Sidoli, O, 2014) |
| "Standardized in vitro wounds were contaminated with Staphylococcus aureus (MRSA; ATCC 33591) and divided into six groups: no dressing (negative control), methacrylate dressing alone, and combinations with application of 0." | 1.39 | Bacterial growth kinetics under a novel flexible methacrylate dressing serving as a drug delivery vehicle for antiseptics. ( Assadian, O; Cutting, KF; Dosch, V; Forstner, C; Kramer, A; Leaper, DJ; Leitgeb, J; Schuster, R, 2013) |
| "In clinical practice, too many chronic wounds are regarded as being at risk of infection, and therefore many topical antimicrobials - in terms of frequency and duration of use - are applied to wounds." | 1.37 | Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation. ( Assadian, O; Dissemond, J; Eberlein, T; Gerber, V; Kingsley, A; Kramer, A; Leaper, DJ; Mosti, G; Piatkowski de Grzymala, A; Riepe, G; Risse, A; Romanelli, M; Strohal, R; Traber, J; Vasel-Biergans, A; Wild, T, 2011) |
| "Chronic wounds are commonly observed in acute and community settings." | 1.35 | Topical antimicrobial agents for the treatment of chronic wounds. ( McIntosh, C; Ousey, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, J | 1 |
| Chen, ZL | 1 |
| Xiang, Y | 1 |
| Tang, T | 1 |
| Zhou, H | 1 |
| Hong, XD | 1 |
| Fan, H | 1 |
| Zhang, XD | 1 |
| Luo, PF | 1 |
| Ma, B | 1 |
| Wang, GY | 1 |
| Xia, ZF | 1 |
| Salamone, AB | 1 |
| Salamone, JC | 1 |
| McMahon, RE | 1 |
| Poleon, S | 1 |
| Bionda, N | 1 |
| D'Arpa, P | 1 |
| Wiegand, C | 1 |
| Eberlein, T | 3 |
| Andriessen, A | 1 |
| Barrett, S | 1 |
| Payne, B | 1 |
| Simmen, HP | 1 |
| Csuka, E | 1 |
| Hintzpeter, M | 1 |
| Pahl, S | 1 |
| Brill, FHH | 1 |
| Forstner, C | 1 |
| Leitgeb, J | 1 |
| Schuster, R | 1 |
| Dosch, V | 1 |
| Kramer, A | 4 |
| Cutting, KF | 1 |
| Leaper, DJ | 3 |
| Assadian, O | 2 |
| Back, DA | 1 |
| Scheuermann-Poley, C | 1 |
| Willy, C | 1 |
| Durante, CM | 1 |
| Greco, A | 1 |
| Sidoli, O | 1 |
| Maino, C | 1 |
| Gallarini, A | 1 |
| Ciprandi, G | 1 |
| Wu, CC | 1 |
| Chew, KY | 1 |
| Chen, CC | 1 |
| Kuo, YR | 1 |
| Harding, K | 1 |
| Bellingeri, A | 1 |
| Falciani, F | 1 |
| Traspedini, P | 1 |
| Moscatelli, A | 1 |
| Russo, A | 1 |
| Tino, G | 1 |
| Chiari, P | 1 |
| Peghetti, A | 1 |
| Hurlow, J | 1 |
| Davis, SC | 1 |
| Harding, A | 1 |
| Gil, J | 1 |
| Parajon, F | 1 |
| Valdes, J | 1 |
| Solis, M | 1 |
| Higa, A | 1 |
| Valenzuela, AR | 1 |
| Perucho, NS | 1 |
| Ousey, K | 1 |
| McIntosh, C | 1 |
| Goertz, O | 1 |
| Abels, C | 1 |
| Knie, U | 1 |
| May, T | 1 |
| Hirsch, T | 1 |
| Daigeler, A | 1 |
| Steinau, HU | 1 |
| Langer, S | 1 |
| Hammann, A | 1 |
| Huebner, NO | 1 |
| Bender, C | 1 |
| Ekkernkamp, A | 1 |
| Hartmann, B | 1 |
| Hinz, P | 1 |
| Kindel, E | 1 |
| Koban, I | 1 |
| Koch, S | 1 |
| Kohlmann, T | 1 |
| Lademann, J | 1 |
| Matthes, R | 1 |
| Müller, G | 1 |
| Titze, R | 1 |
| Weltmann, KD | 1 |
| Dissemond, J | 2 |
| Gerber, V | 2 |
| Riepe, G | 2 |
| Strohal, R | 2 |
| Vasel-Biergans, A | 2 |
| Kingsley, A | 1 |
| Mosti, G | 1 |
| Piatkowski de Grzymala, A | 1 |
| Risse, A | 1 |
| Romanelli, M | 1 |
| Traber, J | 1 |
| Wild, T | 1 |
| Minnich, KE | 1 |
| Stolarick, R | 1 |
| Wilkins, RG | 1 |
| Chilson, G | 1 |
| Pritt, SL | 1 |
| Unverdorben, M | 1 |
| Schultz, G | 1 |
| Carville, K | 1 |
| Fletcher, J | 1 |
| Swanson, T | 1 |
| Drake, R | 1 |
| Motta, GJ | 1 |
| Milne, CT | 1 |
| Corbett, LQ | 1 |
| Wechselberger, F | 1 |
| Roth, B | 1 |
| Baltzer, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Micro/Nanobubbles (MNBs) and Wound Therapy: A Pilot Study Involving a Novel Oxygen Delivery System for Treatment of Acute and Chronic Wounds[NCT05169814] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2021-10-09 | Recruiting | ||
| A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel[NCT03369756] | 43 participants (Actual) | Interventional | 2018-02-20 | Terminated (stopped due to Terminated due to prolonged subject recruitment) | |||
| Kerlix AMD Gauze Study In A Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients[NCT00656708] | 108 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Body consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Body Subscore change, Baseline / Week 1 to Week 2 | Body Subscore change, Baseline / Week 1 to Week 3 | Body Subscore change, Baseline / Week 1 to Week 4 | Body Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.76 | -0.93 | -1.19 | -1.17 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Everyday Life consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Everyday Life Subscore change, Baseline / Week 1 to Week 2 | Everyday Life Subscore change, Baseline / Week 1 to Week 3 | Everyday Life Subscore change, Baseline / Week 1 to Week 4 | Everyday Life Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.58 | -0.82 | -1.11 | -1.00 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Psyche consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Psyche Subscore change, Baseline / Week 1 to Week 2 | Psyche Subscore change, Baseline / Week 1 to Week 3 | Psyche Subscore change, Baseline / Week 1 to Week 4 | Psyche Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.77 | -1.04 | -1.24 | -1.26 |
Change in wound size from Baseline/Week 1 to Final/Week 5. The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5). These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement). (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | wound surface area (cm^2) (Mean) | |
|---|---|---|
| Pre-Debridement Wound Size Change (Baseline/Week 1 to Week 5 / End) | Post-Debridement Wound Size Change(Baseline/Week 1 to Final/Week 5) | |
| Prontosan Solution and Gel | -6.6 | -8.2 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice.~Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A Total or Global score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 / Baseline | Week 2 | Week 3 | Week 4 | Week 5 / End | |
| Prontosan Solution and Gel | 2.41 | 1.74 | 1.51 | 1.25 | 1.30 |
2 reviews available for biguanides and Injuries
| Article | Year |
|---|---|
Recommendations on negative pressure wound therapy with instillation and antimicrobial solutions - when, where and how to use: what does the evidence show?
Topics: Acetic Acid; Anti-Infective Agents, Local; Biguanides; Cross Infection; Evidence-Based Medicine; Hum | 2013 |
Extending the TIME concept: what have we learned in the past 10 years?(*).
Topics: Abbreviations as Topic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anxiety; Bandages; Bigu | 2012 |
5 trials available for biguanides and Injuries
| Article | Year |
|---|---|
Randomized controlled clinical trial on the antiseptic efficacy of polihexanide 0.04% on acute traumatic wounds.
Topics: Adult; Aged; Anti-Infective Agents, Local; Bacterial Load; Biguanides; Colony Count, Microbial; Doub | 2018 |
Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT.
Topics: Aged; Aged, 80 and over; Bandages; Betaine; Biguanides; Chronic Disease; Female; Humans; Inflammatio | 2016 |
[The effectiveness of a 0.1% polyhexanide gel].
Topics: Administration, Topical; Biguanides; Debridement; Gels; Health Policy; Humans; Pressure Ulcer; Treat | 2008 |
Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel.
Topics: Adult; Aged; Anti-Infective Agents, Local; Bandages; Biguanides; Female; Gels; Humans; Informed Cons | 2010 |
Impact of antimicrobial gauze on bacterial colonies in wounds that require packing.
Topics: Aged; Aged, 80 and over; Bandages; Biguanides; Colony Count, Microbial; Diabetic Foot; Disinfectants | 2004 |
18 other studies available for biguanides and Injuries
| Article | Year |
|---|---|
Development of a PHMB hydrogel-modified wound scaffold dressing with antibacterial activity.
Topics: Acinetobacter baumannii; Animals; Anti-Infective Agents, Local; Bandages; Biguanides; Disinfectants; | 2020 |
Synergistic Effect and Antibiofilm Activity of a Skin and Wound Cleanser.
Topics: Biguanides; Biofilms; Detergents; Drug Synergism; Edetic Acid; Glyceryl Ethers; Humans; Methicillin- | 2020 |
Antibacterial activity of polihexanide formulations in a co-culture of HaCaT keratinocytes and Staphylococcus aureus and at different pH levels.
Topics: Anti-Bacterial Agents; Bandages; Biguanides; Coculture Techniques; Humans; Hydrogen-Ion Concentratio | 2017 |
Wound-bed preparation: a vital step in the healing process.
Topics: Administration, Cutaneous; Anti-Bacterial Agents; Anti-Infective Agents, Local; Biguanides; Biofilms | 2017 |
Bacterial growth kinetics under a novel flexible methacrylate dressing serving as a drug delivery vehicle for antiseptics.
Topics: Animals; Anti-Infective Agents, Local; Bandages; Betaine; Biguanides; Disinfectants; Drug Delivery S | 2013 |
Evaluation of the effectiveness of a polyhexanide and propyl betaine-based gel in the treatment of chronic wounds.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Betaine; Biguanides; Child; C | 2014 |
Antimicrobial-impregnated dressing combined with negative-pressure wound therapy increases split-thickness skin graft engraftment: a simple effective technique.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bandages; Biguanides; Chronic Disease; Female | 2015 |
Prologue: transformational healing solutions.
Topics: Anti-Infective Agents, Local; Bandages; Biguanides; Humans; Negative-Pressure Wound Therapy; Practic | 2015 |
The benefits of using polyhexamethylene biguanide in wound care.
Topics: Bandages; Biguanides; Biofilms; Disinfectants; Humans; Wound Infection; Wounds and Injuries | 2017 |
Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model.
Topics: Animals; Betaine; Biguanides; Biofilms; Disease Models, Animal; Disinfectants; Methicillin-Resistant | 2017 |
[Treatment of ulcus cruris and other chronic wounds. Waiting can cost the foot].
Topics: Biguanides; Chronic Disease; Drug Therapy, Combination; Humans; Leg Ulcer; Silver; Wound Healing; Wo | 2008 |
Topical antimicrobial agents for the treatment of chronic wounds.
Topics: Administration, Topical; Anti-Bacterial Agents; Bandages; Biguanides; Chronic Disease; Disinfectants | 2009 |
Antiseptic efficacy and tolerance of tissue-tolerable plasma compared with two wound antiseptics on artificially bacterially contaminated eyes from commercially slaughtered pigs.
Topics: Animals; Anti-Infective Agents, Local; Antisepsis; Bacteria; Biguanides; Colony Count, Microbial; Co | 2010 |
A practice-oriented recommendation for treatment of critically colonised and locally infected wounds using polihexanide.
Topics: Acute Disease; Bacterial Infections; Biguanides; Chronic Disease; Contraindications; Disinfectants; | 2010 |
Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Biguanides; Humans; Immu | 2011 |
The effect of a wound care solution containing polyhexanide and betaine on bacterial counts: results of an in vitro study .
Topics: Betaine; Biguanides; Colony Count, Microbial; Humans; In Vitro Techniques; Wounds and Injuries | 2012 |
[Local management of wounds using the Biotensid wound spray].
Topics: Aerosols; Biguanides; Humans; Wound Infection; Wounds and Injuries | 1975 |
[Preventive intraoperative irrigation in wound management with Lavasept. Report of experiences with 1,610 cases].
Topics: Anti-Infective Agents, Local; Biguanides; Humans; Surgical Wound Infection; Therapeutic Irrigation; | 1990 |